Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Claire Mazumdar, PhD, MBA, Chief Executive Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET.
The presentation will be accessible via live webcast through the Events and Presentations section, with a replay available for viewing after the event.
Bicara Therapeutics (Nasdaq: BCAX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie bifunzionali per tumori solidi, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Claire Mazumdar, PhD, MBA, Amministratore Delegato, terrà una presentazione lunedì 3 marzo 2025, alle 15:10 ET.
La presentazione sarà accessibile tramite webcast dal vivo nella sezione Eventi e Presentazioni, con una registrazione disponibile per la visione dopo l'evento.
Bicara Therapeutics (Nasdaq: BCAX), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias bifuncionales para tumores sólidos, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. Claire Mazumdar, PhD, MBA, Directora Ejecutiva, realizará una presentación el lunes 3 de marzo de 2025, a las 3:10 p.m. ET.
La presentación será accesible a través de una transmisión en vivo en la sección de Eventos y Presentaciones, con una repetición disponible para su visualización después del evento.
비카라 테라퓨틱스 (Nasdaq: BCAX), 고형 종양을 위한 이중 기능 치료제를 개발하는 임상 단계의 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 클레어 마주문다르, PhD, MBA, 최고 경영자(CEO)는 2025년 3월 3일 월요일 오후 3시 10분 ET에 발표를 진행할 예정입니다.
발표는 이벤트 및 프레젠테이션 섹션을 통해 실시간 웹캐스트로 접근 가능하며, 이벤트 후 재생이 가능합니다.
Bicara Therapeutics (Nasdaq: BCAX), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies bifonctionnelles pour les tumeurs solides, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. Claire Mazumdar, PhD, MBA, Directrice Générale, fera une présentation le lundi 3 mars 2025, à 15h10 ET.
La présentation sera accessible via une diffusion en direct dans la section Événements et Présentations, avec une rediffusion disponible après l'événement.
Bicara Therapeutics (Nasdaq: BCAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von bifunktionalen Therapien für solide Tumoren konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Claire Mazumdar, PhD, MBA, Geschäftsführerin, wird am Montag, den 3. März 2025, um 15:10 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast in der Rubrik Veranstaltungen und Präsentationen zugänglich sein, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- None.
- None.
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
A live webcast of the presentation will be available at Events and Presentations. A replay of the webcast will be archived and available following the event.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Bicara Therapeutics (BCAX) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Bicara Therapeutics' (BCAX) TD Cowen conference presentation?
Who will represent Bicara Therapeutics (BCAX) at the 2025 TD Cowen Healthcare Conference?
What type of therapies is Bicara Therapeutics (BCAX) developing?
